{
    "organizations": [],
    "uuid": "92ac089ad8414546a10e675e9d74b9cd87a6806a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cellink-collaboration-with-ctibiot/brief-cellink-collaboration-with-ctibiotech-idUSASM000HSQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Cellink: Collaboration With Ctibiotech",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Cellink Ab:\n* CELLINK SIGNS COLLABORATION AGREEMENT WITH CTIBIOTECH FOR BIOPRINTING OF PATIENT-SPECIFIC CANCER TUMORS\n* ‍COST OF DEVELOPING A NEW DRUG IS NOW ESTIMATED AT $2.5 BILLION OVER 10 YEARS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-08T15:06:00.000+02:00",
    "crawled": "2018-01-09T17:15:32.049+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "cellink",
        "ab",
        "cellink",
        "sign",
        "collaboration",
        "agreement",
        "ctibiotech",
        "bioprinting",
        "cancer",
        "tumor",
        "developing",
        "new",
        "drug",
        "estimated",
        "billion",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}